Ocugen, Inc.
OCGN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OCGN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OCGN
Ocugen, Inc. is a clinical-stage biotechnology company developing gene therapies for retinal diseases, including Stargardt disease, geographic atrophy, and retinitis pigmentosa, with a focus on modifying disease progression.
Key risk: Clinical trial delays or failures
BioSniper Score
Based on 6 of 6 signals
Market Cap
$447.6M
Cash Runway
25.2 moLead Asset
neocart (Phase 3)
Next Catalyst
Phase3_Topline · Sep 28, 2026Financial data as of Jun 30, 2026.
Tracking 8 pipeline candidates · 7 clinical trials · 3 catalysts for Ocugen, Inc..
Ocugen, Inc. is a clinical-stage biotechnology company developing gene therapies for retinal diseases, including Stargardt disease, geographic atrophy, and retinitis pigmentosa, with a focus on modifying disease progression.
- Lead candidate OCU410 is in Phase 3 for geographic atrophy secondary to dry AMD, with a registrational study topline expected in 2031 [sec_mda · as of 2026-08-06].
- OCU410ST is in Phase 1/2 for Stargardt disease, with a Phase 3 topline expected in 2026-09-28 [catalyst].
- Cash and equivalents were $100.4M as of 2026-06-30, with net income of -$24.9M for the same period [latest reported financials].
- The company raised $22.5M in a January 2026 registered direct offering led by RTW Investments [sec · filed 2026-04-28].
- OCU200 for diabetic macular edema is in Phase 1, and OCU400 for retinitis pigmentosa is in Phase 1/2 [catalyst].
What works
- Strong cash position of $100.4M as of 2026-06-30 provides runway for ongoing trials [latest reported financials].
- Multiple pipeline candidates address large retinal disease markets with unmet need [sec_mda · as of 2026-08-06].
- Key secondary endpoint of preservation of Ellipsoid Zone (EZ) may serve as an early indicator of therapeutic benefit [sec · filed 2026-04-28].
What to weigh
- As of March 31, 2026, cash of $31.9M was insufficient to meet capital requirements over the next 12 months, though subsequent financing improved the position [sec_mda · as of 2026-05-08].
- Demonstrating functional benefit via visual acuity within 12 months is challenging due to the disease's natural history [sec · filed 2026-04-28].
- The company has a history of net losses, with a net loss of $24.9M in the six months ended 2026-06-30 [latest reported financials].
From the filings
Quoted directly from source documents.
Preservation of EZ as early indicator of benefit
“it is believed that preservation of EZ will serve as a meaningful and early indicator of therapeutic benefit”
SEC filings · April 28, 2026
January 2026 equity offering led by RTW Investments
“the Company secured $22.5 million in gross proceeds through an underwritten registered direct offering of common stock led by RTW Investments”
SEC filings · April 28, 2026
Catalyst timeline
- 2026-09-28 · Phase 3 Topline for OCU410ST (Stargardt disease) — Topline results from a Phase 1/2 study assessing safety and efficacy of OCU410ST for Stargardt disease.
- 2027-02-12 · Phase 3 Topline for OCU410 (geographic atrophy) — Topline results from a Phase 2/3 study assessing efficacy, safety, and tolerability of OCU410 for geographic atrophy.
- 2031-07-30 · Phase 3 Topline for OCU410 (registrational study) — Topline results from a Phase 3 registrational study assessing efficacy, safety, and tolerability of OCU410 for geographic atrophy.
Risks & what to watch (3)›
Key risks
- Clinical trial delays or failures — Phase 3 topline results for OCU410ST are expected in 2026-09-28, but delays or negative outcomes could impact pipeline [catalyst].
- Cash runway uncertainty — As of March 31, 2026, cash was insufficient for 12 months; subsequent financing improved but ongoing burn remains [sec_mda · as of 2026-05-08].
- Regulatory and manufacturing costs — Future funding depends on costs of trials, FDA submissions, and commercialization, which are uncertain [sec_mda · as of 2026-08-06].
What to watch
- Phase 3 topline data for OCU410ST in Stargardt disease expected 2026-09-28 [catalyst].
- Phase 3 topline data for OCU410 in geographic atrophy expected 2027-02-12 [catalyst].
- Cash burn rate and any additional financing needs given net losses [latest reported financials].
- Progress of OCU200 Phase 1 trial for diabetic macular edema [catalyst].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Ocugen, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ocugen, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
25.2 months
OCF -$12M · Net income -$25M
Lead: Phase 2/Phase 3
8 candidates
3 upcoming, next in ~29d
1 buy · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
134
Total value held
$201.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 27,608,222 | $50.0M |
| millennium management llc | 13,932,192 | $25.2M |
| state street corp | 9,670,191 | $17.5M |
| marshall wace, llp | 8,052,350 | $14.6M |
| blackrock, inc. | 7,304,979 | $13.2M |
| rtw investments, lp | 6,666,666 | $12.1M |
| geode capital management, llc | 4,227,104 | $7.7M |
| jane street group, llc | 3,767,655 | $6.8M |
| gmt capital corp | 3,505,398 | $6.3M |
| citadel advisors llc | 3,179,957 | $5.8M |
Showing top 10 of 134 institutional holders of Ocugen, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 21.0%
- Days to cover
- 7.4
- Shares short
- 67,890,507
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OCGN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Ocugen, Inc.?
Ocugen, Inc. is a clinical-stage biotechnology company developing gene therapies for retinal diseases, including Stargardt disease, geographic atrophy, and retinitis pigmentosa, with a focus on modifying disease progression.
What is Ocugen, Inc.'s lead drug candidate?
Ocugen, Inc.'s most advanced tracked candidate is neocart (Phase 3) for Repair of knee cartilage injuries in adults.
What is Ocugen, Inc.'s next catalyst?
Ocugen, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PI" — expected September 28, 2026.
Who is the CEO of Ocugen, Inc.?
Dr. Shankar Musunuri M.B.A., Ph.D. is the chief executive officer of Ocugen, Inc. (OCGN).
Where is Ocugen, Inc. headquartered?
Ocugen, Inc. (OCGN) is headquartered in Malvern, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.